Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

ting timelines, and safety of the Company's products and technologies. Any statement describing the Company's expectations or beliefs is a forward- looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward- looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings: "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business" and "If our product candidates do not meet safety and efficacy endpoints in clinical trials, they will not receive regulatory approval, and we will be unable to market them". Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise,


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... and a better understanding of climate change are in ... University Belfast,s Institute of Electronics, Communications and Information Technology ... high performance electronic device - known as a dual ... be used in future European Space Agency (ESA) missions. ...
... Recent advances in modern manufacturing techniques,has made it ... high accuracies.,In direct response to the extreme demands ... and,position of microsystem parts, extensive research,is being carried ... micro-scale. , ,Microparts, is a joint EURAMET research ...
... ST. LOUIS, Aug. 7 KV Pharmaceutical Company (NYSE: KVa/KVb) (the ... Company,s Class A and Class B Common Stock, as further described ... purported to have been taken by such Reporting Persons on August ... By-Laws and is therefore invalid and not effective. , , ...
Cached Biology Technology:Research breakthrough will lead to more accurate weather forecasts 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 3KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 4KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 5KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 6
(Date:10/16/2014)... Conn. , October 16, 2014 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... its leading edge technologies including Wocket™, the Smart Wallet, ... (FiRe) Conferenece. FiRe is a leading global conference on ... Hosted by Mark Anderson , founder and ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... Monkeys living on an island without big cat predators do ... played to them, according to research by a UC Davis ... hurry from the sound of human voices. "This contributes ... relaxed selection pressures," said Jessica Yorzinski, a graduate student in ...
... much more significant role in a persons ability to ... than previously understood, say scientists. Writing in Nature ... nutrients in the environment are critical to the fitness ... The findings for the first time provide a ...
... NEW YORK (Jan. 16, 2008) -- Two major federal grants ... Medical College in New York City. Dr. Kenneth ... NIH grant from the National Institute on Drug Abuse (NIDA) ... prevention program previously delivered to urban minority youth attending New ...
Cached Biology News:Diet and lifestyle critical to recovery, says study 22 federal public health grants awarded to Weill Cornell Medical College 2
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
... is designed for easy transformation of the ... for successful transformation simply by mixing a ... cultured yeast cells. No complicated steps, such ... The kit is particularly well suited for ...
... easier. It offers a wide array of features for ... *Instruments supported: Control ... PR, SR, PG-S, PG, SG, AT, MT, UMT, AB-S, ... User guidance on the balance display ...
... powder ,Components g/500 ml: ... ,Sodium chloride 2.5 ,Agar 6.0 ... 0.250 ,IPTG 0.025 ,Kanamycin 0.0175 ... a complete growth medium containing ...
Biology Products: